Skip to main content
main-content

Glucagon-like peptide-1 agonists

News

06-18-2018 | Dulaglutide | News

Dulaglutide feasible alternative to insulin glargine in patients with CKD

Once-weekly dulaglutide lowers glycated hemoglobin levels to a similar degree to titrated daily insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, study findings indicate.

05-18-2018 | Liraglutide (T2DM) | News

Real-world data support liraglutide use in obese patients

Obese patients with type 2 diabetes who receive treatment intensification with liraglutide may have better glycemic control than those given basal insulin, researchers report.

04-24-2018 | Cardiovascular disorders | Highlight | News

Patients with type 2 diabetes and CVD may receive suboptimal treatment

Specialist physicians and antidiabetic medications reported to confer cardiovascular benefit are being underutilized by patients with type 2 diabetes and cardiovascular disease, US study data show.

Read more

Related topics

Superior

Related

Specific

Opinion

11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

01-13-2017 | Cardiovascular outcomes | Editorial | Article

Clinical implications of cardiovascular outcomes trials in type 2 diabetes

What do the results of CVOTs mean for practicing clinicians? Medicine Matters contributor, Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

In depth

01-15-2018 | Type 1 diabetes | Hot topic review | Article

What do we know about adjunct non-insulin medications in type 1 diabetes?

medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.

10-17-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

Original research

Journal articles and book chapters

05-04-2018 | Sodium-glucose cotransporter-2 inhibitors | Review | Article

Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes

A systematic review and meta-analysis

Zheng et al. JAMA 2018; 319:1580. doi: 10.1001/jama.2018.3024

05-04-2018 | Glucagon-like peptide-1 agonists | Review | Article

Glucagon-like peptide 1 in health and disease

Andersen A et al. Nat Rev Endocrinol 2018; Advance online publication. doi: 10.1038/s41574-018-0016-2

04-05-2018 | Oral combination medications | Review | Article

Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk

Goncalves E, Bell DSH. Diabetes Ther 2018; 9: 919–926. doi: 10.1007/s13300-018-0420-6

In practice

02-16-2017 | Type 2 diabetes | In practice | Article

The role of the pharmacist in managing type 2 diabetes with glucagon-like peptide-1 receptor agonists as add-on therapy

Meece J. Adv Ther 2017; 34: 638–657. doi: 10.1007/s12325-017-0491-1

Case reports

01-15-2018 | Prader-Willi syndrome | Case report | Article

Effectiveness of sodium-glucose cotransporter-2 inhibitor as an add-on drug to GLP-1 receptor agonists for glycemic control of a patient with Prader–Willi syndrome: A case report

The authors report the case of a 36-year-old Japanese male patient with Prader–Willi Syndrome who was treated with a sodium-glucose cotransporter-2 inhibitor to improve glycemic control.

image credits